CTOR logo

CITIUS ONCOLOGY INC

CTORNASDAQ
πŸ† #4210 by market capEarnings Dec 21US Equity
$0.50β–Ό $0.06 (βˆ’10.11%)
Market closed Β· at close
πŸ””
Track CTOR
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 10.1%
7dβ–Ό 9.7%
14dβ–Ό 5.1%
30dβ–Ό 4.8%
ytdβ–Ό 48.7%
1yβ–Ό 56.5%
🏦Market Cap
$47M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.50 – $0.54
52-Week Range
$0.49 – $1.83
Volume (shares)
3,500
Avg Volume (shares)
β€”
Shares Outstanding
93.0M
Next Earnings
2026-12-21

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
$1M
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-0.48
Dividend Yield
β€”
Dilution (1yr)
+22.2%
CTOR logo

CITIUS ONCOLOGY INC

CTOR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$24Mβ–² +14.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$5Mβ–Ό βˆ’4446.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
87.5Mβ–² +22.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3Mβ–² +$7M YoY
StockOtter Β· stockotter.space

About CITIUS ONCOLOGY INC

Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.